No abstract available
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Multicenter Study
MeSH terms
-
Administration, Oral
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Lenalidomide
-
Lymphoma, T-Cell, Peripheral / drug therapy*
-
Lymphoma, T-Cell, Peripheral / pathology
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Prospective Studies
-
Recurrence
-
Remission Induction
-
Thalidomide / administration & dosage
-
Thalidomide / analogs & derivatives*
-
Thalidomide / therapeutic use
-
Thrombocytopenia / chemically induced
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Thalidomide
-
Lenalidomide
Associated data
-
ClinicalTrials.gov/NCT01036399